Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ENDRA Life Sciences Inc. Director's Dealing 2017

May 18, 2017

35444_dirs_2017-05-18_ebc110eb-0a73-49b6-b846-b4f9d73c8917.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2017-05-12

Reporting Person: Tokman Alexander Y (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-05-12 Stock Options $5.00 A 12000 Acquired 2022-05-12 Common Stock (12000) Direct